GlassScriptPhysician profile
Amanda Lee Keown
NPI 1154803666
$7,716.95
in general payments reported to CMS, 2019-2025
30 companies · $1,874 in 2025
The $1,874 reported for 2025 was more than what 93% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,355 · 2022: $1,283 · 2023: $1,353 · 2024: $1,852 · 2025: $1,874.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,079.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,078.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,780.87 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $940.93 | 2021-2025 | Breztri, Airsupra, Farxiga |
| Lilly USA, LLC | $798.40 | 2021-2025 | Mounjaro, Zepbound, Trulicity |
| Takeda Pharmaceuticals U.S.A., INC. | $761.59 | 2021-2025 | Trintellix |
| Amgen INC. | $680.66 | 2021-2025 | Repatha, Otezla, Evenity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $625.13 | 2021-2025 | Jardiance |
| Abbvie INC. | $344.93 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $317.15 | 2023-2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $174.88 | 2021-2022 | |
| Phathom Pharmaceuticals, INC. | $158.13 | 2024-2025 | Voquezna |
| Exact Sciences Corporation | $129.38 | 2023-2025 | Cologuard Collection Kit |
| Pfizer INC. | $112.32 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $105.21 | 2022-2024 | Gardasil 9, Vaxneuvance, Pneumovax 23 |
| E.R. Squibb & Sons, L.L.C. | $105.10 | 2025 | |
| Dexcom, INC. | $79.74 | 2023-2025 | Dexcom G6 Transmitter |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $79.25 | 2021 | |
| Glaxosmithkline, LLC. | $63.77 | 2021-2025 | Trelegy Ellipta |
| Esperion Therapeutics, INC. | $63.43 | 2025 | Nexletol |
| Sumitomo Pharma America, INC. | $53.67 | 2023-2025 | Gemtesa |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $51.13 | 2025 | Caplyta |
| Xeris Pharmaceuticals, INC. | $44.62 | 2022 | |
| Idorsia Pharmaceuticals US INC | $43.78 | 2023 | Quviviq |
| Teva Pharmaceuticals USA, INC. | $37.00 | 2025 | Austedo Xr |
| Astellas Pharma US INC | $34.57 | 2024 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $32.91 | 2022-2023 | |
| Sanofi-Aventis U.S. LLC | $31.48 | 2022 | |
| Medtronic, INC. | $21.28 | 2025 | Interstim |
| Alexion Pharmaceuticals, INC. | $17.86 | 2021 | |
| Novartis Pharmaceuticals Corporation | $15.72 | 2024 | |
| Axsome Therapeutics, INC. | $12.06 | 2025 | Auvelity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Keown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.